Document text
Principal Investigator: Alberto Gandini
Organization: ACCEL DIAGNOSTICS, LLC
Fiscal Year: 2024
Award: $398,753
Funding agency: National Institute of Allergy and Infectious Diseases
Summary
In response to the COVID-19 pandemic and the increasing need of serological testing we propose the
development and clinical validation of a novel serological blood test, RapidQCT™, to aid in the
diagnosis and management of the COVID-19 pandemic. As the case for other viral infections, the
immune system responds to the COVID-19 infection by developing antibodies (IgG and IgM, among
others) against the virus (SARS-COV-2). Antibody titer tests have been a valuable tool to determined
individual immunity to several infection diseases, from rubella, to measles. More importantly, as
COVID-19 vaccines become available, and a large-scale vaccination strategy will take place, the
RapidQCT will help stratify potentially hundred of millions of people and identify who is most likely to
benefit, and sparing those who will not. Because the test can be self-administered by patients, it will
also promote mobile health management of the pandemic, expanding the breadth of testing, and
protecting health care workers from exposure. Current serological tests are binary test, which only
provide a yes/no answer, and therefore unable to provide a full picture of the development the
immunity across the population. On the other hand, the RapidQCT is an easy to use and rapid test
and the first quantitative Point-of-Care (POC) anti-COVID-19 antibody titer test. The size of credit
card, it requires only one drop of blood from finger prick to asses the presence and titer level of anti-
COVID-19 antibodies. The test companion mobile app enables the tracking of the disease spreading,
progression, as well as development of the immunity throughout the population. This project will be
completed in two Phases: Phase I - Aim 1: Fabrication Streamline, Scale-Up, and Assay
Calibration. In this Aim, we will translate from the current lean development phase to the
manufacturing phase. Phase I - Aim 2: Assay Calibration: Here we will determined the assay titer
curve calibration. Phase II - Aim 1: Longitudinal monitoring of COVID-19 specific antibody titers.
The RapidQCT tests will use to follow longitudinally to three groups: Symptomatic Infected (SI),
Asymptomatic Infected (AI), and Not Infected (NI) (control). The trend of the antibody titer for each
group will be stratified by gender, age, pre-conditions, and severity of infection. Phase II - Aim 2:
Longitudinal monitoring of antibody titers in pregnancy. Immunological changes occurring in
COVID-19 positive pregnancy versus the non-pregnant population will be monitored.
This project is the result of an ongoing collaboration between Accel Diagnostics and The University of
Texas Health Science Center at Houston (Houston, TX), and it is expected to deliver a clinically
validated and novel tool to manage the COVID-19 pandemic.
Terms: <19S Gamma Globulin><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><7S Gamma Globulin><Age><Antibodies><Antibody titer measurement><Assay><Bioassay><Biological Assay><Blood><Blood Reticuloendothelial System><Blood Tests><Booster Immunization><COVID crisis><COVID epidemic><COVID monitoring><COVID pandemic><COVID point of care><COVID-19><COVID-19 antibody><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 monitoring><COVID-19 pandemic><COVID-19 period><COVID-19 point of care><COVID-19 positive><COVID-19 positivity><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 virus><COVID-19 virus infection><COVID-19 years><COVID19 infection><COVID19 monitoring><COVID19 virus><CV-19><Calibration><Chicken Pox><Chickenpox><Clinical><CoV-2><CoV2><Collaborations><Companions><Coronavirus Infectious Disease 2019><Data><Developing fetus><Development><Devices><Diagnosis><Diagnostic><Disease><Disease Progression><Disorder><Drops><Emergencies><Emergency Situation><Enrollment><Ensure><Fetal Development><Fingers><Funding><Funding Mechanisms><Gender><German Measles><Gestation><Hand><Health Care Providers><Health Personnel><Health Sciences><Health protection><Healthcare Providers><Healthcare worker><Hearing><Hematologic Tests><Hematological Tests><Hematology Testing><Hepatitis B><Herd Immunity><IRB><IRBs><IgG><IgM><Immune system><Immunity><Immunochemical Immunologic><Immunocompetence><Immunoglobulin G><Immunoglobulin M><Immunologic><Immunologic Competence><Immunological><Immunological Competence><Immunologically><Immunologics><Individual><Infection><Institutional Review Boards><Lateral><Leanness><Legal patent><Licensing><Marketing><Measles><Medicine><Molecular><Monitor><Nucleic Acid Amplification Tests><Nucleic Acid Testing><Outcome><Patents><Patients><Persons><Phase><Physicians><Play><Population><Pregnancy><Preparedness><Process><Protocol><Protocols documentation><Readiness><Reagent><Recommendation><Reproducibility><Rubella><Rubeola><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 monitoring><SARS-CoV-2 pandemic><SARS-CoV-2 point of care><SARS-CoV-2 positive><SARS-CoV-2 positivity><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sample Size><Sampling><Secondary Immunization><Secure><Self Administered><Self Administration><Serology><Serology test><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Coronavirus Syndrome 2 point of care><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 positive><Severe acute respiratory syndrome coronavirus 2 positivity><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severities><Societies><Specificity><Statistical Data Analyses><Statistical Data Analysis><Statistical Data Interpretation><Symptoms><Technology><Temporal trend><Test Result><Testing><Texas><Thinness><Time><Time trend><Translating><Trends over time><Universities><Vaccination><Validation><Varicella><Viral Diseases><Viral Gene Products><Viral Gene Proteins><Viral Hepatitis B><Viral Proteins><Virus><Virus Diseases><Wuhan coronavirus><acquired immunity><ages><antibody against COVID-19><antibody against SARS-CoV-2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody assay><antibody based test><antibody test><antibody titering><antibody to COVID-19><antibody to SARS-CoV-2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><booster vaccination><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 monitoring><coronavirus disease 2019 pandemic><coronavirus disease 2019 point of care><coronavirus disease 2019 positive><coronavirus disease 2019 positivity><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease monitoring><coronavirus disease pandemic><coronavirus disease point of care><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><cost><design><designing><developmental><enroll><expectation><fabrication><hCoV19><hands><health care management><health care personnel><health care worker><health management><health provider><health workforce><healthcare management><healthcare personnel><immunization strategy><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><m-Health><mHealth><manufacture><maternal immune system><medical personnel><microfluidic technology><mobile app><mobile application><mobile device application><mobile health><morbilli><mother immune system><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><novel><pandemic><pandemic disease><point of care><pre-clinical><preclinical><prototype><rapid assay><rapid test><rapid tests><response><scale up><serology assay><serum hepatitis><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 monitoring><statistical analysis><tool><treatment provider><trend><vaccination strategy><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID><validations><viral infection><virus infection><virus protein><virus-induced disease><µfluidic technology>